

Gambro establishes sales company and clinical activity in Turkey

Stockholm, Sweden, August 13, 2002 – Gambro AB (Stockholmsbörsen: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today announced that the company has agreed to acquire all shares in the Bülten dialysis center in Turkey, which also includes the sales and service organizations Intac group, to integrate this into the company's business portfolio.

With this first acquisition in Turkey, Gambro will obtain both clinic activity and a local sales company in the country.

Lennart la Fleur, Managing Director Gambro Export, says, "The acquisition is a clear signal that we intend to move into this strategically important market, a market with more patients than Spain and almost as big as France. With the acquisition we get an immediate market position and a market share of 10-12 percent for dialysis products." The acquisition also includes the biggest dialysis clinic in Ankara, Bülten dialysis center, with currently 125 patients.

The dialysis market in Turkey has been growing by 15 percent per year in the last years, mainly in the private clinic sector. There are some 390 clinics today in the country, of which 35 percent are private. Around 45 percent of all patients are treated in private clinics. The number of dialysis patients is estimated at 24,000.

For further information please contact:

Lennart la Fleur, Managing Director Gambro Export, tel. +46-46-16 92 58, +46-70-818 92 58
Janette Jennische, Vice President, Corporate Communications, tel. +46-8-613 65 99, +46-70-212 50 53
Pia Irell, Investor Relations Director, Corporate Finance, tel. +46-8-613 65 91, +46-70-513 65 91
Kevin Smith, President Gambro Inc., Investor Relations US, tel. +1-303 231 4750

Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology. Gambro Healthcare is one of the leading providers of kidney dialysis services in the world with more than 52,200 patients in 680 clinics worldwide. Gambro Renal Products comprises dialyzers, dialysis machines, blood lines and dialysis concentrates. Gambro BCT is the market leader in separation and handling of blood components. The group, with 2001 revenues of approximately SEK 27 billion (USD 2.7 billion), has 20,600 employees in some 40 countries.

Gambro AB

A public company (publ)
Reg no. 556041-8005
Jakobsgatan 6, PO Box 7373
SE-103 91 Stockholm
Sweden
Tel +46 8-613 65 00
Fax +46 8-611 28 30
info@gambro.com
www.gambro.com